View Older Stories View More Recent Stories

Sep 12, 2022 11:20AM Pfizer and BioNTech Receive Positive CHMP Opinion for Omicron BA.4/BA.5-Adapted Bivalent COVID-19 Vaccine Booster in European Union
Sep 12, 2022 11:20AM Pfizer and BioNTech Receive Positive CHMP Opinion for Omicron BA.4/BA.5-Adapted Bivalent COVID-19 Vaccine Booster in European Union
Sep 1, 2022 09:46AM BioNTech SE (BNTX) and Pfizer (PFE) Receive Positive CHMP Opinion for COVID-19 Vaccine Booster in EU
Sep 1, 2022 09:45AM Pfizer and BioNTech Receive Positive CHMP Opinion for Omicron BA.1-Adapted Bivalent COVID-19 Vaccine Booster in European Union
Sep 1, 2022 09:45AM Pfizer and BioNTech Receive Positive CHMP Opinion for Omicron BA.1-Adapted Bivalent COVID-19 Vaccine Booster in European Union
Sep 1, 2022 09:45AM Pfizer and BioNTech Receive Positive CHMP Opinion for Omicron BA.1-Adapted Bivalent COVID-19 Vaccine Booster in European Union
Aug 31, 2022 10:18AM Pfizer and BioNTech Granted FDA Emergency Use Authorization of Omicron BA.4/BA.5-Adapted Bivalent COVID-19 Vaccine Booster for Ages 12 Years and Older
Aug 31, 2022 10:15AM Pfizer (PFE), BioNTech SE (BNTX) Confirm FDA EUA for Omicron Booster
Aug 31, 2022 10:12AM Pfizer and BioNTech Granted FDA Emergency Use Authorization of Omicron BA.4/BA.5-Adapted Bivalent COVID-19 Vaccine Booster for Ages 12 Years and Older
Aug 31, 2022 10:12AM Pfizer and BioNTech Granted FDA Emergency Use Authorization of Omicron BA.4/BA.5-Adapted Bivalent COVID-19 Vaccine Booster for Ages 12 Years and Older
Aug 26, 2022 09:52AM  Pfizer and BioNTech Complete Submission to European Medicines Agency for Omicron BA.4/BA.5 Adapted Bivalent Vaccine
Aug 26, 2022 09:45AM Pfizer and BioNTech Complete Submission to European Medicines Agency for Omicron BA.4/BA.5 Adapted Bivalent Vaccine
Aug 26, 2022 09:45AM Pfizer and BioNTech Complete Submission to European Medicines Agency for Omicron BA.4/BA.5 Adapted Bivalent Vaccine
Aug 23, 2022 06:45AM Pfizer (PFE) and BioNTech (BNTX) Report Updated COVID-19 Vaccine Data Supporting Efficacy in Children 6 Months through 4 Years Old
Aug 23, 2022 06:45AM Pfizer and BioNTech Announce Updated COVID-19 Vaccine Data Supporting Efficacy in Children 6 Months through 4 Years of Age
Aug 23, 2022 06:45AM Pfizer and BioNTech Announce Updated COVID-19 Vaccine Data Supporting Efficacy in Children 6 Months through 4 Years of Age
Aug 23, 2022 06:45AM Pfizer and BioNTech Announce Updated COVID-19 Vaccine Data Supporting Efficacy in Children 6 Months through 4 Years of Age
Aug 22, 2022 10:31AM BioNTech SE (BNTX) and Pfizer (PFE) Submit FDA Application for EMA of Omicron BA.4/BA.5-Adapted Bivalent COVID-19 Vaccine
Aug 22, 2022 10:30AM Pfizer and BioNTech Submit Application to U.S. FDA for Emergency Use Authorization of Omicron BA.4/BA.5-Adapted Bivalent COVID-19 Vaccine
Aug 22, 2022 10:30AM Pfizer and BioNTech Submit Application to U.S. FDA for Emergency Use Authorization of Omicron BA.4/BA.5-Adapted Bivalent COVID-19 Vaccine
Aug 22, 2022 10:30AM Pfizer and BioNTech Submit Application to U.S. FDA for Emergency Use Authorization of Omicron BA.4/BA.5-Adapted Bivalent COVID-19 Vaccine
Aug 5, 2022 06:46AM Genmab A/S (GMAB) and BioNTech (BNTX) Expand Collaboration to Develop and Commercialize Novel Immunotherapy Candidates
Aug 5, 2022 06:45AM BioNTech and Genmab Expand Global Strategic Collaboration to Develop and Commercialize Novel Immunotherapy Candidates
Aug 5, 2022 06:45AM Genmab and BioNTech Expand Global Strategic Collaboration to Develop and Commercialize Novel Immunotherapy Candidates
Jul 27, 2022 06:47AM BioNTech SE (BNTX) and Pfizer (PFE) Advance COVID-19 Vaccine Strategy With Study Start of Next-Generation Vaccine Candidate Based on Enhanced Spike Protein Design
Jul 27, 2022 06:45AM Pfizer and BioNTech Advance COVID-19 Vaccine Strategy With Study Start of Next-Generation Vaccine Candidate Based on Enhanced Spike Protein Design
Jul 27, 2022 06:45AM Pfizer and BioNTech Advance COVID-19 Vaccine Strategy With Study Start of Next-Generation Vaccine Candidate Based on Enhanced Spike Protein Design
Jun 29, 2022 04:45PM Pfizer (PFE), BioNTech (BNTX) Announce New Agreement with U.S. Government to Provide Additional Doses of COVID-19 Vaccine
Jun 29, 2022 04:45PM Pfizer and BioNTech Announce New Agreement with U.S. Government to Provide Additional Doses of COVID-19 Vaccine
Jun 29, 2022 04:45PM Pfizer and BioNTech Announce New Agreement with U.S. Government to Provide Additional Doses of COVID-19 Vaccine
Jun 29, 2022 04:45PM Pfizer and BioNTech Announce New Agreement with U.S. Government to Provide Additional Doses of COVID-19 Vaccine
Jun 27, 2022 05:58AM BioNTech SE (BNTX) and Pfizer (PFE) Report Omicron-Adapted COVID-19 Vaccine Candidates Demonstrate High Immune Response Against
Jun 25, 2022 10:02AM Pfizer and BioNTech Announce Omicron-Adapted COVID-19 Vaccine Candidates Demonstrate High Immune Response Against Omicron
Jun 25, 2022 10:02AM Pfizer and BioNTech Announce Omicron-Adapted COVID-19 Vaccine Candidates Demonstrate High Immune Response Against Omicron
Jun 25, 2022 10:00AM Pfizer and BioNTech Announce Omicron-Adapted COVID-19 Vaccine Candidates Demonstrate High Immune Response Against Omicron
Jun 17, 2022 09:24AM Pfizer (PFE) and BioNTech (BNTX) COVID-19 Vaccine Receives FDA Emergency Use Authorization for Children 6 Months through 4 Years of Age
Jun 17, 2022 09:24AM Pfizer-BioNTech COVID-19 Vaccine Receives FDA Emergency Use Authorization for Children 6 Months through 4 Years of Age
Jun 17, 2022 09:22AM Pfizer-BioNTech COVID-19 Vaccine Receives FDA Emergency Use Authorization for Children 6 Months through 4 Years of Age
Jun 17, 2022 09:22AM Pfizer-BioNTech COVID-19 Vaccine Receives FDA Emergency Use Authorization for Children 6 Months through 4 Years of Age
May 23, 2022 06:45AM Pfizer (PFE) -BioNTech (BNTX) COVID-19 Vaccine Demonstrates Strong Immune Response, High Efficacy and Favorable Safety in Children 6 Months to Under 5 Years of Age Following Third Dose
May 23, 2022 06:45AM Pfizer-BioNTech COVID-19 Vaccine Demonstrates Strong Immune Response, High Efficacy and Favorable Safety in Children 6 Months to Under 5 Years of Age Following Third Dose
May 23, 2022 06:45AM Pfizer-BioNTech COVID-19 Vaccine Demonstrates Strong Immune Response, High Efficacy and Favorable Safety in Children 6 Months to Under 5 Years of Age Following Third Dose
May 23, 2022 06:45AM Pfizer-BioNTech COVID-19 Vaccine Demonstrates Strong Immune Response, High Efficacy and Favorable Safety in Children 6 Months to Under 5 Years of Age Following Third Dose
May 17, 2022 11:40AM Pfizer (PFE), BioNTech (BNTX) Confirm EUA for Booster Dose of Their COVID-19 Vaccine in Children 5 Through 11 Years of Age
May 17, 2022 11:40AM Pfizer and BioNTech Granted U.S. Emergency Use Authorization for Booster Dose of Their COVID-19 Vaccine in Children 5 Through 11 Years of Age
Apr 14, 2022 06:46AM Pfizer (PFE) and BioNTech SE (BNTX) Report Data Demonstrating High Immune Response Following a Booster Dose of their COVID-19 Vaccine in Children Aged 5-11
Apr 14, 2022 06:45AM Pfizer and BioNTech Announce Data Demonstrating High Immune Response Following a Booster Dose of their COVID-19 Vaccine in Children 5 Through 11 Years of Age
Apr 14, 2022 06:45AM Pfizer and BioNTech Announce Data Demonstrating High Immune Response Following a Booster Dose of Their COVID-19 Vaccine in Children 5 Through 11 Years of Age
Mar 29, 2022 10:31AM Pfizer (PFE), BioNTech (BNTX) Receive Expanded U.S. Emergency Use Authorization for an Additional COVID-19 Vaccine Booster in Individuals Aged 50 Years and Older
Mar 29, 2022 10:30AM  Pfizer and BioNTech Receive Expanded U.S. Emergency Use Authorization for an Additional COVID-19 Vaccine Booster in Individuals Aged 50 Years and Older
View More Recent Stories View Older Stories